• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ASO Author Reflections: The Pursuit of Eliminating Surgery after Neoadjuvant Systemic Therapy in Breast Cancer Patients.

作者信息

van Loevezijn Ariane A, van Duijnhoven Frederieke H, Vrancken Peeters Marie-Jeanne T F D

机构信息

Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.

出版信息

Ann Surg Oncol. 2021 Jun;28(6):3254-3255. doi: 10.1245/s10434-020-09324-6. Epub 2020 Dec 10.

DOI:10.1245/s10434-020-09324-6
PMID:33301068
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8119248/
Abstract
摘要

相似文献

1
ASO Author Reflections: The Pursuit of Eliminating Surgery after Neoadjuvant Systemic Therapy in Breast Cancer Patients.ASO作者反思：追求消除乳腺癌患者新辅助全身治疗后的手术
Ann Surg Oncol. 2021 Jun;28(6):3254-3255. doi: 10.1245/s10434-020-09324-6. Epub 2020 Dec 10.
2
ASO Author Reflections: Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer: Is It Oncologically Safe?ASO作者反思：新辅助化疗后对淋巴结阳性乳腺癌进行前哨淋巴结手术：从肿瘤学角度看是否安全？
Ann Surg Oncol. 2020 Dec;27(Suppl 3):707-708. doi: 10.1245/s10434-020-08954-0. Epub 2020 Jul 31.
3
ASO Author Reflections: Tailoring Axillary Surgery After Neoadjuvant Endocrine Therapy for Breast Cancer.ASO作者反思：新辅助内分泌治疗后乳腺癌腋窝手术的个体化选择
Ann Surg Oncol. 2021 Mar;28(3):1368-1369. doi: 10.1245/s10434-020-09435-0. Epub 2021 Jan 2.
4
ASO Author Reflections: Low Rates of Axillary Recurrence in Clinically Node-Positive Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy Alone Following Pathologic Response to Neoadjuvant Chemotherapy.ASO作者反思：新辅助化疗病理反应后仅接受前哨淋巴结活检的临床淋巴结阳性乳腺癌患者腋窝复发率低
Ann Surg Oncol. 2021 May;28(5):2630-2631. doi: 10.1245/s10434-020-09259-y. Epub 2020 Oct 29.
5
ASO Author Reflections: Sentinel Lymph Node Removal After Neoadjuvant Chemotherapy in Clinically Node-Negative Patients Can Stop After Removal of Three Lymph Nodes.ASO作者反思：临床淋巴结阴性患者新辅助化疗后前哨淋巴结切除在切除三个淋巴结后可停止。
Ann Surg Oncol. 2020 Dec;27(Suppl 3):848-849. doi: 10.1245/s10434-020-08874-z. Epub 2020 Jul 21.
6
ASO Author Reflections: Improving Patient Selection for Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy.《美国外科医师学会（ASO）作者反思：改善新辅助化疗后前哨淋巴结活检的患者选择》
Ann Surg Oncol. 2018 Dec;25(Suppl 3):640-641. doi: 10.1245/s10434-018-6851-5. Epub 2018 Oct 9.
7
ASO Author Reflections: How Predictive Models Can Help Guide Axillary Surgery Decision Making After Neoadjuvant Chemotherapy.ASO作者反思：预测模型如何帮助指导新辅助化疗后腋窝手术的决策制定
Ann Surg Oncol. 2020 Dec;27(Suppl 3):690-691. doi: 10.1245/s10434-020-08933-5. Epub 2020 Jul 28.
8
ASO Author Reflections: Moving Forward De-escalation of Axillary Surgery After Neoadjuvant Treatment in Breast Cancer.ASO作者反思：乳腺癌新辅助治疗后推进腋窝手术降阶梯治疗
Ann Surg Oncol. 2018 Dec;25(Suppl 3):638-639. doi: 10.1245/s10434-018-6849-z. Epub 2018 Oct 3.
9
ASO Author Reflections: Omission of Axillary Lymph Node Dissection for Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy: Not Ready for Primetime?ASO作者反思：新辅助化疗后仍有N1淋巴结残留疾病的乳腺癌患者省略腋窝淋巴结清扫术：时机尚不成熟？
Ann Surg Oncol. 2020 Dec;27(Suppl 3):869-870. doi: 10.1245/s10434-020-08966-w. Epub 2020 Jul 31.
10
ASO Author Reflections: Neoadjuvant Systemic Therapy and Nodal Management in cT1-2 N0 Triple-Negative Breast Cancer.ASO作者反思：cT1-2 N0三阴性乳腺癌的新辅助全身治疗与淋巴结管理
Ann Surg Oncol. 2024 May;31(5):3196-3197. doi: 10.1245/s10434-024-15020-6. Epub 2024 Feb 10.

引用本文的文献

1
Biopsy-Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial.乳腺癌活检引导的病理反应评估不充分：MICRA 试验的其他病理发现。
Ann Surg Oncol. 2023 Aug;30(8):4682-4689. doi: 10.1245/s10434-023-13476-6. Epub 2023 Apr 18.